Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: Emphasis on sampling variability

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 7, 2005, Pages 1109-1114

  Lee, Hsuan Shu ^a   Shun, Chia Tung ^a   Chiou, Ling Ling ^a   Chen, Chien Hung ^a   Huang, Guan Tarn ^a   Sheu, Jin Chuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Histological staging; Hydroxyproline; Liver fibrosis; Needle biopsy; Sampling variability

Indexed keywords

COLLAGEN; HYDROXYPROLINE;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LIVER TUMOR; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; SAMPLING; SCORING SYSTEM;

EID: 21844436061     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03901.x     Document Type: Article

References (26)

1. Sherlock S, Dooley J. Diseases of the Liver and Biliary System, 11th edn. Oxford: Blackwell Science, 2002.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
3. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000; 132: 517-24.
4. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch. Intern. Med. 1979; 139: 667-9.
5. Maharaj B, Maharaj RJ, Leary WP et al Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; i: 523-5.
6. Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J. Clin. Pathol. 1996; 49: 556-9.
7. Lee HS, Huang GT, Miau LH, Chiou LL, Chen CH, Sheu JC. Expression of matrix metalloproteinases in spontaneous regression of liver fibrosis. Hepatogastroenterology 2001; 48: 1114-17.
8. Lee HS, Huang GT, Chen CH et al. Less reversal of liver fibrosis after prolonged carbon tetrachloride injection. Hepatogastroenterology 2001; 48: 1312-15.
9. The METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20: 15-20.
10. Ellis AJ, Curry VA, Powell EK, Cawston TE. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem. Biophys. Res. Commun. 1994; 201: 94-101.
11. Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal. Chem. 1962; 35: 1961-5.
12. Braunstein H. Needle biopsy of the liver in cirrhosis: diagnostic efficiency as determined by post-mortem sampling. Arch. Pathol. 1956; 62: 87-95.
13. Olsson R, Hagerstrand I, Broome U et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J. Clin. Pathol. 1995; 48: 933-5.
14. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-9.
15. Fanning L, Loane J, Kenny-Walsh E et al. Tissue viral load variability in chronic hepatitis C. Am. J. Gastroenterol. 2001; 96: 3384-9.
16. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. J. Gastroenterol. Hepatol. 1999; 14: 618-33.
17. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol Chem. 2000; 275: 2247-50.
18. Pihlajaniemi T, Myllyla R, Kivirikko KI. Prolyl 4-hydroxylase and its role in collagen synthesis. J. Hepatol. 1991; 13 (Suppl. 3): S2-7.
19. Adams E, Frank L. Metabolism of proline and the hydroxyprolines. Annu. Rev. Biochem. 1980; 49: 1005-61.
20. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
21. George J. Biochemical markers of hepatic fibrogenesis: single measurements are not reliable enough to replace liver biopsy. J. Gastroenterol. Hepatol. 2000; 15: 819-21.
22. Afdhal NH. Diagnosing fibrosis in hepatitis C. Is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37: 972-4.
23. Lucidarme O, Baleston F, Cadi M et al. Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur. Radiol. 2003; 13: 467-74.
24. Oberti F, Valsesia E, Pilette C et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-16.
25. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
26. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.